|
|
 |
|
Viewing report
|
|
|
|
Asthma & COPD Therapeutics
Greystone Associates, March 2008
As the number of asthmatics, COPD, and allergy patients continues to grow, the upper respiratory treatment market is attracting a number of new companies – companies with some novel approaches to the problem of chronic airway inflammation and reactive airway disease. These companies are conducting ongoing research into the way asthma and COPD are diagnosed and measured, minimally invasive techniques to treat airway congestion, and technology improvements focused on systemic delivery of proteins and peptides as well as novel small molecule therapeutics. New drug classes that focus on molecular targets are emerging as important tools for practitioners. Interest is growing among practitioners and their patients for treatments that are capable of delivering two drugs that can act in concert to mitigate the effects of airway inflammation and reactive airway disease better than a single drug. These combination products pair drugs with different indications to maximize patient relief
Asthma and COPD Therapeutics: Evolving Treatments, Emerging Opportunities is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the respiratory therapeutics sector.
Published in March (2008), the report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of upper respiratory therapeutics and diagnostics on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication. Evolving Upper Respiratory Healthcare Solutions A significant opportunity exists to improve and expand current treatment of respiratory diseases. The inhaled respiratory market represents one of the largest categories of drug spending, with continuing growth due to increasing incidence and diagnosis of asthma and chronic obstructive pulmonary disease. Interest is growing among practitioners and their patients for inhalers that are capable of delivering two drugs that can act in concert to mitigate the effects of upper respiratory disease better than a single drug. These combination products pair drugs with different indications to maximize patient relief.
This report provides detailed information and analysis on private companies that are developing new drugs and medical devices to address unmet needs in the upper respiratory disease sector.
Feature Summary
This report provides detailed information and data on the critical factors and issues that are driving the development of emerging therapeutics for upper
respiratory conditions
- Upper Respiratory Disease Demographics & Growth Factors
- Existing Therapeutic Assessment
- Emerging Pipeline Candidate Analysis
- Near-term Therapeutic Sector Impact
- Drug Product Strategic Factors
- Upper Respiratory Disease Sector Outlook
- Market Factors and Treatment Issues
- Combination Drug-Device Strategies
Customers who bought this item also bought
Asthma Therapeutics: New Treatment Options and Emerging Drug Discovery Targets
European Asthma Therapeutics Markets
Commercial Insight: Asthma & COPD - On the verge of generic entry
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Airway Smooth Muscle in Asthma and COPD: Biology and Pharmacology
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Pipeline Insight: Asthma, Copd and Allergic Rhinitis - The Needs of Severe Patients Must be Addressed
U.S. Asthma Therapeutics Market
Drug Therapeutics: Therapeutic Proteins
Asthma And COPD - Get Smart
COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease
Emerging Drug Targets in Alzheimer's Disease
|
|
|
|
